Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2021 | 2021-11-08 | Future report Set alerts | |
Q2 2021 | 2021-08-05 | -0.20 | -0.20 |
Q1 2021 | 2021-05-11 | -0.24 | -0.24 |
Q4 2020 | 2021-03-16 | -0.28 | -0.28 |
Q3 2020 | 2020-11-09 | -0.31 | -0.31 |
Q2 2020 | 2020-08-05 | 0.60 | 0.60 |
Q1 2020 | 2020-05-07 | -0.58 | -0.58 |
Q4 2019 | 2020-03-16 | -0.40 | -0.40 |
Q3 2019 | 2019-11-12 | -0.39 | -0.39 |
Q2 2019 | 2019-08-01 | -0.37 | -0.37 |
2016-05-17 | Reiterated Rating | BMO Capital Markets | Market Perform | $5.00 to $7.00 |
2015-11-17 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $14.00 to $5.00 |
2015-08-13 | Reiterated Rating | Roth Capital | Hold | |
2014-12-04 | Downgrade | Craig Hallum | Buy to Hold | |
2014-12-04 | Downgrade | Leerink Swann | Outperform to Market Perform | $11.25 to $6.00 |
2014-12-04 | Reiterated Rating | BMO Capital Markets | Outperform | $19.00 to $14.00 |
2014-08-21 | Lower Price Target | BMO Capital Markets | $30.00 to $19.00 | |
2014-08-21 | Lower Price Target | Leerink Swann | $29.00 to $11.25 | |
2014-08-21 | Lower Price Target | Roth Capital | $11.50 | |
2014-05-23 | Initiated Coverage | Craig Hallum | Buy | |
2014-05-13 | Boost Price Target | Leerink Swann | $29.00 to $32.00 | |
2014-05-13 | Lower Price Target | Roth Capital | $18.00 to $17.00 | |
2014-04-14 | Initiated Coverage | Leerink Swann | Outperform | $32.00 |
2014-04-08 | Lower Price Target | Roth Capital | $25.00 to $18.00 | |
2014-03-07 | Downgrade | Roth Capital | Buy to Neutral | $20.00 to $25.00 |
2014-02-25 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $15.00 to $30.00 |
2014-02-04 | Initiated Coverage | Roth Capital | Buy | $20.00 |
2014-01-22 | Downgrade | BMO Capital Markets | Outperform to Market Perform | |
2014-01-06 | Initiated Coverage | Guggenheim | Buy | |
2014-01-06 | Initiated Coverage | BMO Capital Markets | Outperform | $15.00 |
2016-05-17 | Reiterated Rating | BMO Capital Markets | Market Perform | $5.00 to $7.00 |
2015-11-17 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $14.00 to $5.00 |
2015-08-13 | Reiterated Rating | Roth Capital | Hold | |
2014-12-04 | Downgrade | Craig Hallum | Buy to Hold | |
2014-12-04 | Downgrade | Leerink Swann | Outperform to Market Perform | $11.25 to $6.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In KIN 14 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
QS Investors, LLC | 76200 |
JACKSON PARK CAPITAL, LLC | 69000 |
Osborn Rohs Williams & Donohoe Ltd | 62700 |
BlackRock Institutional Trust Company, N.A. | 58390 |
TEACHERS ADVISORS INC | 57607 |
TIAA CREF INVESTMENT MANAGEMENT LLC | 56843 |
BlackRock Fund Advisors | 44361 |
BLACKROCK ADVISORS LLC | 23195 |
KCG Holdings, Inc. | 15285 |
BlackRock Group LTD | 14850 |
BlackRock Investment Management, LLC | 2994 |
BlackRock Japan Co. Ltd | 2203 |
LADENBURG THALMANN FINANCIAL SERVICES INC | 1000 |
BOSTON PRIVATE BANK & TRUST CO | 700 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Park West Asset Management LLC | 26.16% (5156791) | INAP / KIN / OUTR / WLRH / |
Chin Richard President and CEO | 11.39% (2246071) | GALE / KIN / OXGN / |
NODELMAN OLEG | 3.12% (614495) | KIN / |
MARIO ERNEST | 0.51% (99583) | BSX / CAPN / CELG / CMRX / KIN / TNXP / VVUS / XNPT / |
Bevers Denise Chief Operating Officer | 0.45% (88630) | KIN / |
Wee Wendy Chief Financial Officer | 0.16% (30718) | KIN / TELK / |
Zhan Hangjun Chief Scientific Officer | 0.15% (29147) | KIN / |
Townsend Raymond | 0.14% (27928) | KIN / |